Investment
Features
FeesSafety
Academy
More
Pluang+

Millrose Properties stock falls 29% on business model shifts, but core land-banking remains strong.

Analyst Insights
14 Oct 2026
Seeking Alpha
View Source
Bullish
Millrose Properties stock falls 29% on business model shifts, but core land-banking remains strong.

Millrose Properties (MRP) shares have dropped 29% since September due to concerns about changes in its business model and its new single-family rental (SFR) initiative. Despite the stock decline, MRP's core land-banking business remains solid with strong protections and good builder margins that reduce downside risk. The SFR venture adds complexity but is not viewed as enough to justify the stock's steep discount to its book value. The analyst upgrades MRP to a "Strong Buy" rating with a $30 price target, considering the SFR risks manageable and not a reason to avoid the stock.

Millrose Properties shares and their recent market context are shown here for readers. Of 47 priced Real Estate-sector US stocks tradable on Pluang, 31 rose and 11 fell today. Notable movers include AIV at USD 1.76 with 0% Sell / 100% Buy Pluang order activity, AHR at USD 53.41, and CTRE at USD 37.10. This data is as of Oct 14, 2026 15:41 WIB.

More News

CodeWall raises $4M to launch AI-driven autonomous attack agents for continuous enterprise security testing.

CodeWall raises $4M to launch AI-driven autonomous attack agents for continuous enterprise security testing.

CodeWall Ltd. has emerged from stealth with $4 million in pre-seed funding to develop AI-powered autonomous attack agents that simulate real-world cyberattacks on enterprises. These agents start from outside the network with no insider access, contin...

Others
Bullish
1 hour ago
Matchpoint Therapeutics names John O’Malley as Chief Medical Officer to advance autoimmune drug pipeline.

Matchpoint Therapeutics names John O’Malley as Chief Medical Officer to advance autoimmune drug pipeline.

Matchpoint Therapeutics has appointed John O’Malley, M.D., Ph.D., as its Chief Medical Officer. Dr. O’Malley brings extensive experience in immunology and clinical development from his previous roles at CRISPR Therapeutics and Sanofi. His leadership ...

Market News
Bullish
2 hours ago
FDA accepts Orvida Pharma's KM-023 into Rare Disease Evidence Principles process for Olmsted syndrome

FDA accepts Orvida Pharma's KM-023 into Rare Disease Evidence Principles process for Olmsted syndrome

Orvida Pharma announced that the FDA has accepted its lead drug candidate KM-023 (ontivatrep) into the Rare Disease Evidence Principles (RDEP) process for treating Olmsted syndrome, a rare genetic skin disorder. This acceptance allows Orvida to engag...

Market News
Bullish
2 hours ago
DMC Global to release Q3 2026 financial results on October 27 after market close

DMC Global to release Q3 2026 financial results on October 27 after market close

DMC Global Inc. will announce its financial results for the third quarter ending September 30, 2026, on October 27 after the stock market closes. The company will hold a conference call and webcast to discuss the results, providing investors with ins...

Company Fundamentals
Neutral
2 hours ago
Radware launches MCP Server Protection to secure AI integration layers from attacks and abuse.

Radware launches MCP Server Protection to secure AI integration layers from attacks and abuse.

Radware introduced its Model Context Protocol (MCP) Server Protection solution to help organizations secure the integration layer where AI agents connect to enterprise applications and workflows. This new security tool provides visibility into MCP in...

Market News
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App